Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

J. Richter, A. Lübking, S. Söderlund, K. Lotfi, B. Markevärn, A. Själander, L. Stenke, S. Deneberg, E. Ahlstrand, K. Myhr-Eriksson, P. Panayiotidis, T. Gedde-Dahl, D. Žáčková, J. Mayer, U. Olsson-Strömberg, FX. Mahon, S. Saussele, H....

. 2021 ; 35 (8) : 2416-2418. [pub] 20210215

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21025244
E-resources Online Full text

NLK ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Nursing & Allied Health Database (ProQuest) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago
Public Health Database (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 33589755
DOI 10.1038/s41375-021-01173-w
Knihovny.cz E-resources

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025244
003      
CZ-PrNML
005      
20211026134007.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-021-01173-w $2 doi
035    __
$a (PubMed)33589755
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Richter, Johan $u Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. johan.richter@med.lu.se
245    10
$a Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI / $c J. Richter, A. Lübking, S. Söderlund, K. Lotfi, B. Markevärn, A. Själander, L. Stenke, S. Deneberg, E. Ahlstrand, K. Myhr-Eriksson, P. Panayiotidis, T. Gedde-Dahl, D. Žáčková, J. Mayer, U. Olsson-Strömberg, FX. Mahon, S. Saussele, H. Hjorth-Hansen, P. Koskenvesa
650    _2
$a klinické zkoušky jako téma $x metody $7 D002986
650    _2
$a bcr-abl fúzní proteiny $x genetika $7 D016044
650    _2
$a lidé $7 D006801
650    _2
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $x patologie $7 D015464
650    _2
$a lokální recidiva nádoru $x chemicky indukované $x diagnóza $x epidemiologie $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a inhibitory proteinkinas $x škodlivé účinky $7 D047428
650    _2
$a indukce remise $7 D012074
650    _2
$a časové faktory $7 D013997
650    _2
$a nenasazení léčby $x statistika a číselné údaje $7 D028761
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lübking, Anna $u Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
700    1_
$a Söderlund, Stina $u Department of Medical Sciences, University of Uppsala and Section of Hematology, Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Lotfi, Kourosh $u Department of Hematology, University Hospital, Linköping, Sweden
700    1_
$a Markevärn, Berit $u Department of Hematology, University Hospital, Umeå, Sweden
700    1_
$a Själander, Anders $u Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
700    1_
$a Stenke, Leif $u Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Deneberg, Stefan $u Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Ahlstrand, Erik $u Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
700    1_
$a Myhr-Eriksson, Kristina $u Department of Hematology, Sunderby Hospital, Luleå, Sweden
700    1_
$a Panayiotidis, Panayiotis $u First Department of Propedeutic Medicine, Laikon Hospital, National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Gedde-Dahl, Tobias $u Oslo University Hospital, Oslo, Norway
700    1_
$a Žáčková, Daniela $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Mayer, Jiří $u Department of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Olsson-Strömberg, Ulla $u Department of Medical Sciences, University of Uppsala and Section of Hematology, Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Mahon, Francois-Xavier $u Laboratoire Hématopoïèse Leucémique et cible thérapeutique, INSERM U876, Université Victor Ségalen Bordeaux 2, Bordeaux, France
700    1_
$a Saussele, Susanne $u Medizinische Universitätsklinik Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
700    1_
$a Hjorth-Hansen, Henrik $u Department of Hematology, St Olavs Hospital, Trondheim, Norway
700    1_
$a Koskenvesa, Perttu $u Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 35, č. 8 (2021), s. 2416-2418
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33589755 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134013 $b ABA008
999    __
$a ok $b bmc $g 1714343 $s 1145751
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 8 $d 2416-2418 $e 20210215 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20211013
Back

Find record

Citation metrics

Archiving options